This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action
Blood Cancer Journal Open Access 13 March 2021
-
Bcl-xL inhibition enhances Dinaciclib-induced cell death in soft-tissue sarcomas
Scientific Reports Open Access 07 March 2019
-
CDK9 inhibitors in acute myeloid leukemia
Journal of Experimental & Clinical Cancer Research Open Access 23 February 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Grever MR, Lucas DM, Johnson AJ, Byrd JC . Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia. Best Pract Res Clin Haematol 2007; 20: 545–556.
Byrd JC, Shinn C, Waselenko JK, Fuchs EJ, Lehman TA, Nguyen PL et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 1998; 92: 3804–3816.
Konig A, Schwartz GK, Mohammad RM, Al-Katib A, Gabrilove JL . The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 1997; 90: 4307–4312.
Kitada S, Zapata JM, Andreeff M, Reed JC . Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000; 96: 393–397.
Phelps MA, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 2009; 113: 2637–2645.
Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009; 27: 6012–6018.
Paruch K, Dwyer MP, Alvarez C, Brown C, Chan T-Y, Doll RJ et al. Discovery of dinaciclib (SCH 727965): a potent and selective inhibitor of cyclin-dependent kinases. ACS Med Chem Lett 2010; 1: 204–208.
Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, Wiswell D et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther 2010; 9: 2344–2353.
Niedermeier M, Hennessy BT, Knight ZA, Henneberg M, Hu J, Kurtova AV et al. Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 2009; 113: 5549–5557.
Hussain SR, Lucas DM, Johnson AJ, Lin TS, Bakaletz AP, Dang VX et al. Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium. Blood 2008; 111: 3190–3199.
Woyach JA, Lozanski G, Ruppert AS, Lozanski A, Blum KA, Jones JA et al. Outcome of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) treated with flavopiridol: Impact of Genomic Features. Leukemia 2012; 26: 1442–1444.
Acknowledgements
We thank all of the patients who donated blood for these studies and also the clinical support staff who collected them. All statistical evaluation was done by the OSU Center for Biostatistics. This work was supported by Specialized Center of Research from the Leukemia and Lymphoma Society, K12 CA133250, P50-CA140158, P01 CA95426, P01 CA8153 and P01 CA101956 from the National Cancer Institute, Pelotonia Fellowship Program and The D Warren Brown Foundation. AJJ is a Paul Calabresi Scholar and Y-YY is a Pelotonia post-doctoral fellow.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
RB is an employee of Merck and Co.
Additional information
Authorship Contribution
LLS, AJW, JH, and Y-YY performed the experiments. LLS, AJJ, and JCB analyzed the results and made the figures. XZ performed the statistical analysis. JF, JJ, MRG, and JCB provided clinical samples. AJJ, RB, MRG and JCB designed the research and wrote the paper.
Supplementary Information accompanies the paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Johnson, A., Yeh, YY., Smith, L. et al. The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells. Leukemia 26, 2554–2557 (2012). https://doi.org/10.1038/leu.2012.144
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2012.144
This article is cited by
-
The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action
Blood Cancer Journal (2021)
-
Bcl-xL inhibition enhances Dinaciclib-induced cell death in soft-tissue sarcomas
Scientific Reports (2019)
-
CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia
Investigational New Drugs (2019)
-
CDK9 inhibitors in acute myeloid leukemia
Journal of Experimental & Clinical Cancer Research (2018)
-
Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity
Scientific Reports (2016)